1. Home
  2. UEC vs IBRX Comparison

UEC vs IBRX Comparison

Compare UEC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Uranium Energy Corp.

UEC

Uranium Energy Corp.

HOLD

Current Price

$13.05

Market Cap

6.6B

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.22

Market Cap

7.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEC
IBRX
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
7.5B
IPO Year
2008
2015

Fundamental Metrics

Financial Performance
Metric
UEC
IBRX
Price
$13.05
$7.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$18.95
$12.57
AVG Volume (30 Days)
8.7M
11.9M
Earning Date
06-01-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.71
EPS
N/A
N/A
Revenue
$66,837,000.00
$113,288,000.00
Revenue This Year
N/A
$88.59
Revenue Next Year
$220.11
$131.15
P/E Ratio
N/A
N/A
Revenue Growth
29737.95
668.31
52 Week Low
$5.63
$1.95
52 Week High
$20.34
$12.43

Technical Indicators

Market Signals
Indicator
UEC
IBRX
Relative Strength Index (RSI) 42.95 43.25
Support Level $11.86 $6.64
Resistance Level $14.64 $8.51
Average True Range (ATR) 1.04 0.60
MACD -0.30 -0.05
Stochastic Oscillator 24.46 3.90

Price Performance

Historical Comparison
UEC
IBRX

About UEC Uranium Energy Corp.

Uranium Energy Corp is a uranium mining company engaged in the exploration, extraction, and processing of uranium and titanium concentrates across projects in the United States, Canada, and Paraguay. The Company operates through multiple segments, including uranium mining activities in Wyoming, Texas, Saskatchewan, and other regions, along with a corporate segment focused on investments and uranium inventory trading. It is expanding its portfolio of low-cost uranium projects in stable North American locations and operates a Wyoming-based ISR (In-Situ Recovery) Hub and Spoke platform. This platform is supported by two fully operational central processing plants and seven U.S. ISR uranium projects.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: